Credit: Shutterstock

Lil­ly, No­vo’s bet on heart dis­ease starts to take shape, and 2024 could be a piv­otal year for their GLP-1s 

Eli Lil­ly and No­vo Nordisk are steadi­ly — and some­what qui­et­ly — prepar­ing to build com­pre­hen­sive car­dio­vas­cu­lar fran­chis­es helmed by their lu­cra­tive treat­ments for di­a­betes and obe­si­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.